RecruitMe Clinical Trial

An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Sponsor:Global Coalition for Adaptive Research
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS2589
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

You are being invited to take part the control arm of a research study that includes studying radiation in combination with Temozolomide or Lomustine in newly diagnosed or recurrent brain tumors. Below you will find a summary of key information about this research study that will explain what the study is about, what you will be asked to do, how long you may be in the study, and the risks and benefits of participating in the study. The purpose of this study is evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. The procedures in this study are research blood draws, physical exams and collection of your medical history, MRI scans, and study drug administration. If you have newly diagnosed GBM, you will receive radiation therapy 5 times a week for 6 weeks and Temozolomide daily for 6 weeks, then a 2-6 week rest period, followed by 2 maintenance cycles.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have a newly diagnosed or recurrent glioblastoma?YesNo
Are you willing and able to provide written informed consent and to comply with the study protocol?YesNo
Submit
Cancel
Investigator
Andrew Lassman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162